Posted in | News | Medical Sensor

Endosense Launches Force-Sensing TactiCath 75 Catheter in Europe

Endosense, a medical technology company focused on improving safety, accessibility and efficacy associated with catheter ablation for treating cardiac arrhythmias has launched the TactiCath 75 force-sensing ablation catheter in Europe and has released the results of the EFFICAS I clinical trial to demonstrate the effect of contact force in catheter ablation procedures.

Endosense Tacticath

The TactiCath 75 is a steerable, open irrigated radiofrequency ablation catheter that uses the force-sensingfiber optic sensor technology employed in the earlier models of the TactiCath. However, the TactiCath 75 is an 8.5 F sheath compatible catheter featuring a 75 mm long curved tip. Commercially available in Europe through Biotronik, the exclusive distributer of TactiCath for Canada, Europe, Africa, Latin America and the Middle East, the TactiCath 75 provides increased safety of cardiac ablation procedures and provides decision-making time for the physician, thus reducing duration of the procedures.

The results of the European post-market study of the TactiCath during cardiac ablation procedures, EFFICAS I, were also released by Endosense. EFFICASI is a 46-patient trial designed to determine the association between contact forces applied during pulmonary vein isolation (PVI) and the efficacy of atrial fibrillation treatment. The investigators recorded the applied contact forces while performing the procedures using the TactiCath. After a three-month period, the patients were reassessed to isolate gaps in the PVI lines. Based on the lesion formation and contact force parameters, the investigators determined that with a minimum force of 10 g and Force-Time Integral of 400 g seconds, the continuous line of ablation points achieved were more successful in electrical isolation per pulmonary vein segment. Investigators have recorded these FTI parameters and minimum force as the guidelines for the EFFICAS II clinical trial.

The President and CEO of Endosense, Jan Keltjens stated that the result of the EFFICAS study demonstrates the importance of contact-force sensing. Furthermore, the study proved that non-transmural lesions can be reduced or avoided using FTI information and force. The results of the EFFICAS II study will be announced in a few months.

Source:  https://www.cardiovascular.abbott/us/en/home.html

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Endosense SA. (2022, July 13). Endosense Launches Force-Sensing TactiCath 75 Catheter in Europe. AZoSensors. Retrieved on May 23, 2024 from https://www.azosensors.com/news.aspx?newsID=3704.

  • MLA

    Endosense SA. "Endosense Launches Force-Sensing TactiCath 75 Catheter in Europe". AZoSensors. 23 May 2024. <https://www.azosensors.com/news.aspx?newsID=3704>.

  • Chicago

    Endosense SA. "Endosense Launches Force-Sensing TactiCath 75 Catheter in Europe". AZoSensors. https://www.azosensors.com/news.aspx?newsID=3704. (accessed May 23, 2024).

  • Harvard

    Endosense SA. 2022. Endosense Launches Force-Sensing TactiCath 75 Catheter in Europe. AZoSensors, viewed 23 May 2024, https://www.azosensors.com/news.aspx?newsID=3704.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.